perspectivesI've held shares in Resverlogix for about 5 years. I've followed this bullboard for about 6 months and find it helpful. I do not plan to sell my shares and I do not plan to short them.
Of course regarding the value of the company everything is speculation at this stage. However, my observations are as follows:
- The results from the post hoc analysis are extremely postive (based on the Feb 2014 webcast) on every dimension within the specific sub-segment (high risk CVD with low HDL - still a very large market - potentially $14 billion as stated in the webcast) when used in conjunction with Crestor.
- The MACE findings are so positive that they should accelerate the next trial to phase 3.
- The HDL-P performance, once independently verified, should boost interest in RVX-208.
- I'm sure or at least hopeful that there are many good efforts going on that can't be discussed publicly e.g. discussions with AstraZenica and others.
- They seem to be strong on the science side but I'm not so sure about the business side. To give them credit they still exist after 14 years.
- I sense their corporate culture is an "inventor" culture and totally lacking in the entrepreneurial drive. I've invested in "inventor" type companies and they love their creations and never really care if they get to market as long as each year they can find some money to keep things moving ahead.
- I don't know Don, never talked to him, but in the webcasts he sounds solid and steady but he might need some help on the business, public relations, marketing and finance side of things.
- Based on the webcasts the business plans sound weak. With the fantastic post hoc findings things should be moving fast. I know that science takes time but the business aspect should move with speed.
- The loss of Arthur Higgins could be good or bad but my take is that he came in, checked out the business and science and decided there are bigger opportunities elsewhere. Not good for Resverlogix. However, if there is something happening with Blackburn perhaps there was a conflict of interest.
- I guess that the fact that Eastern Capital holds 20% of the shares does suggest they have some hope in the company.
- On the Zenith side of the business I was actually stunned in February when they did not announce concrete, high priority plans for an IPO. There seems to be no sense of urgency for a sub IPO even though the small pharma IPO market is hot!!! Strike when the iron is hot.
They've got their work cut out trying to raise $25,000,000 for RVX 208 phase 2c trials and also raise money for salaries and overheads. They should have a heavy hitter lobbying the FDA to accelerate RVX 208.
Anyway, I'm sure all of this has been discussed before. I remain positive. The results seem incredible. On the Zenith side they must get off their duff's and get an IPO issued!
Cheers
toinv